TP53 / del(17p) in B-Cell Lymphomas: A Predictive Biomarker That Redirects Therapy

Why this marker matters

Few molecular findings change a management conversation as decisively as a TP53 aberration. The gene sits on the short arm of chromosome 17 and encodes p53, the transcription factor that commits a genotoxically stressed cell to cell-cycle arrest or apoptosis. When chemotherapy and chemoimmunotherapy work, much of their killing runs through exactly this p53-dependent apoptotic checkpoint. So when TP53 is disabled — whether by deletion of the locus or by a pathogenic point mutation — the tumour cell loses the very machinery those drugs depend on. That's the biological heart of why this is a predictive marker rather than a merely prognostic one: it tells us something about what a class of drugs can and can't accomplish.

In the current classifications of lymphoid neoplasms, TP53 status is recognised as a clinically actionable feature in several mature B-cell entities [1,2]. In practice, what I find worth emphasising to trainees is that the two assays below aren't redundant — they interrogate two genuinely different ways the same gene gets silenced.

What the test measures

p53 function can be lost through two complementary mechanisms. The first is deletion of the 17p region containing TP53, detected by fluorescence in situ hybridisation (FISH) as del(17p). The second is a pathogenic sequence mutation within the gene, detected by next-generation sequencing (NGS). A tumour can carry one, the other, or — commonly — both, with a mutation on one allele and deletion of the partner allele producing biallelic inactivation. Because either lesion alone can compromise p53 output, testing only for deletion will miss cases driven by mutation, and vice versa. That's why dual-platform assessment is the standard approach.

How it's tested

FISH for del(17p) is performed on interphase nuclei from blood, marrow, or FFPE tissue using a locus-specific probe, with a laboratory-validated percentage of nuclei required before a deletion is called positive. NGS for TP53 mutation sequences the coding exons and reports variants with an assigned pathogenicity and a variant allele fraction (VAF) — the proportion of sequenced alleles carrying the change.

Specimen quality drives everything downstream. FFPE material can fragment DNA and introduce sequencing artefacts, so preanalytic fixation and adequate tumour cellularity matter. For blood and marrow, the proportion of tumour cells in the sample sets the sensitivity ceiling: a low-burden sample can dilute a real mutation below the detection threshold. Scoring is reported as a binary — deletion and/or pathogenic mutation present versus absent — yielding two result states: TP53 aberrant or TP53 intact.

What each result means

A TP53 aberrant result — del(17p), a pathogenic mutation, or both — marks a tumour whose p53-dependent apoptotic response is impaired. Across B-cell lymphomas this carries adverse weight, and in chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) it directly reshapes the therapeutic decision.

A TP53 intact result means neither lesion was detected at the assay's limits. It doesn't guarantee normal p53 biology — subclonal or below-threshold events can escape detection — but it removes this particular contraindication to standard chemoimmunotherapy backbones.

What it determines for treatment eligibility

The clinical logic is straightforward: if a drug kills partly through p53, and p53 is broken, expect that drug to underperform. In CLL and MCL, a TP53 aberration accordingly steers management away from chemoimmunotherapy and toward targeted agents that act largely independently of the p53 checkpoint — the BTK inhibitors and the BCL2 inhibitor class. A TP53 aberrant result therefore informs eligibility for BTK- and BCL2-inhibitor-based approaches rather than dictating any individual's regimen. As an illustration, the CLL2-GIVe trial evaluated a chemotherapy-free combination of obinutuzumab, ibrutinib, and venetoclax specifically in previously untreated del(17p)/TP53-mutated CLL — a population defined by this very biomarker [3].

In MCL the same principle applies, with the added nuance that TP53 mutation has emerged as one of the more powerful adverse molecular features, often tracking with aggressive blastoid or pleomorphic morphology and resistance to intensive cytarabine-containing induction — one reason MCL work-ups increasingly pair morphology with molecular TP53 assessment.

Caveats and what's still evolving

The binary report hides real biological texture. The most frequent interpretive challenge in daily practice is the borderline result — a mutation sitting at a low VAF, or a FISH deletion in a small fraction of nuclei. Where a small subclone crosses the line into clinical significance is genuinely contested, and laboratories differ in the thresholds they've validated. A 5% VAF call in one lab won't necessarily be reported the same way in another, and that variability can matter at the point of care. When a VAF hovers near the reporting floor, I'd rather flag it explicitly and recommend a repeat on a higher-cellularity specimen than force it into a clean binary.

Two other points deserve emphasis. Discordance between platforms is expected, not alarming: FISH-positive/NGS-negative and the reverse both occur, which is precisely why both assays earn their place. And TP53 status isn't static — clones carrying these lesions can be selected and expand under treatment pressure, so a result reflects one moment in an evolving disease rather than a fixed property.

That last point is where the interesting work now sits. As sequencing sensitivity improves, we're detecting TP53 subclones far earlier and far smaller than the thresholds our predictive data were built on — and whether a 1–2% clone at diagnosis carries the same weight as a dominant one remains an open, and clinically consequential, question worth watching closely.

References

1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the WHO Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022. doi:10.1038/s41375-022-01620-2

2. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms. Blood. 2022. doi:10.1182/blood.2022015851

3. Huber H, et al. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut. 2023. PMID:37363867